Condition

Head and Neck Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 309 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials309

Recruiting62

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Effects of Infusion Timing on Treatment Response in Solid TumorsNCT07630168 · 2026-08-03

A Study of a New PET Scanner in People With CancerNCT07690917 · 2026-06-30

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid MalignanciesNCT07613723 · 2026-05-11

18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsNCT07557225 · 2026-04-27

Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)NCT07524114 · 2026-03-31

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCNCT07462377 · 2026-03-31

Distance-Based Exercise to Preserve Function and Prevent DisabilityNCT07059884 · 2026-02-11

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot TrialNCT07447050 · 2025-12-23

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsNCT07358806 · 2025-12-18

To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.NCT06970275 · 2025-11-19

DESTINY-PANTUMOUR04NCT07124000 · 2025-09-18

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsNCT07020117 · 2025-08-22

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499 · 2025-08-20

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsNCT07085091 · 2025-08-18

Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051 · 2025-07-21

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)NCT07327489 · 2025-04-14

Ovarian-Sparing Adaptive Radiotherapy in Young Adult WomenNCT06904365 · 2025-04-08

Clonal Hematopoiesis Chemotherapy and Radiation Effects StudyNCT07675967 · 2025-04-04

Brodalumab in the Treatment of Immune-Related Adverse EventsNCT06673329 · 2025-03-11

Extracellular Vesicles and Chemotherapy-Induced Peripheral NeuropathyNCT07558447 · 2025-01-01

Trop2-targeted immunoPET Imaging of Solid TumorsNCT06851663 · 2024-12-23

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialNCT06580002 · 2024-12-02

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsNCT06239194 · 2024-06-12

PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR SurvivorsNCT06124508 · 2024-04-11

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478 · 2024-02-26

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsNCT06265025 · 2024-02-20

Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) CancerNCT05874492 · 2024-01-29

MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)NCT06041555 · 2024-01-08

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for CancerNCT05787834 · 2023-10-16

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)NCT06116019 · 2023-10-11

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)NCT06103669 · 2023-10-05

Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)NCT06691776 · 2023-08-29

High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection MarginsNCT06835426 · 2023-08-06

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New TechnologyNCT05184790 · 2023-02-28

Improving Care for Rural Patients With Solid TumorsNCT04916990 · 2022-09-01

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)NCT05403177 · 2022-06-23

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseNCT05366881 · 2022-05-03

ATATcH Alternating Treatment Plans for Advanced CancerNCT05358548 · 2022-04-28

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsNCT05076760 · 2022-04-21

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated TumorsNCT05313191 · 2022-01-24

Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsNCT05187338 · 2021-11-01

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsNCT04930432 · 2021-09-24

RAPA-201 Therapy of Solid TumorsNCT05144698 · 2021-08-01

AB122 Platform StudyNCT04999761 · 2021-06-01

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750 · 2020-10-29

Jump: MR Simulation For Radiation Therapy Master ProtocolNCT04545957 · 2020-10-14

EXCEL: Exercise for Cancer to Enhance Living WellNCT04478851 · 2020-09-02

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityNCT04273061 · 2020-06-17

Deciphering Mechanisms Underlying Cancer ImmunogenicityNCT03958240 · 2020-01-17

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766 · 2019-12-10

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid TumorsNCT04354064 · 2019-05-29

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyNCT04075305 · 2019-02-01

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsNCT03787056 · 2018-12-04

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid TumorsNCT03755739 · 2018-11-01

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-LinacNCT04172753 · 2018-05-09

Liquid Biopsy Evaluation and Repository Development at Princess MargaretNCT03702309 · 2017-08-03

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)NCT03017573 · 2017-01-06

Immunobiology Blood and Tissue Collection of Upper Aerodigestive MalignanciesNCT05995821 · 2016-08-25

Ontario-wide Cancer TArgeted Nucleic Acid EvaluationNCT02906943 · 2016-08-01

Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck CancersNCT03908684 · 2014-12-17

Common interventions

Leading sponsors

Incyte Corporation7 Memorial Sloan Kettering Cancer Center7 National Cancer Institute (NCI)7 Washington University School of Medicine6 M.D. Anderson Cancer Center5 University Health Network, Toronto5 Vanderbilt-Ingram Cancer Center5 Alliance for Clinical Trials in Oncology4 Celldex Therapeutics4 Masonic Cancer Center, University of Minnesota4 Pfizer4 Roswell Park Cancer Institute4 Siemens Molecular Imaging4 Stanford University4 Fate Therapeutics3

Trial status mix

COMPLETED151

RECRUITING62

TERMINATED34

UNKNOWN28

ACTIVE_NOT_RECRUITING12

NOT_YET_RECRUITING10

WITHDRAWN7

AVAILABLE2

APPROVED_FOR_MARKETING1

ENROLLING_BY_INVITATION1

SUSPENDED1

Phase mix

PHASE1116

PHASE271

NA70

PHASE38

PHASE45

EARLY_PHASE14

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.